+39 02 610346.1 - info@newron.com

Press Releases

Filter by year
  • march252017

    Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia

     

  • march212017

    FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS

     

  • march162017

    Newron to Present at the 16th International Congress on Schizophrenia Research

     

  • march22017

    Newron announces 2016 financial results and provides outlook for 2017 Board approves agenda for AGM on March 28, 2017

     

  • february212017

    Newron Supports Global Rare Disease Day® 2017 and Rett Syndrome Studies

     

  • january102017

    Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand

  • january32017

    Evenamide met study objectives of good tolerability, safety, and preliminary evidence of efficacy as an add-on therapy for the treatment of schizophrenia- unique MoA